VAQTA is indicated for the prevention of disease caused by hepatitis A
virus (HAV) in persons 12 months of age and older.
The primary dose should
be given at least 2 weeks prior to expected exposure to HAV.
Signup to K2
Register today for a Kays Medical trade account and begin using K2 to place orders securely and conveniently for immediate delivery.
Click here to signup or if already registered click here to login.